Reaction: Mirabegron to 1 product

Reaction
Reaction type
glucuronidation; oxidation
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T: Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23. [Article]
  2. Konishi K, Tenmizu D, Takusagawa S: Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective beta3-Adrenoceptor Agonist, in Human Liver Microsomes. Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):301-309. doi: 10.1007/s13318-017-0450-x. [Article]
  3. FDA Approved Drug Products: MYRBETRIQ (mirabegron) extended-release tablets or granules, for oral use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableimplied
Cytochrome P450 2D6Not AvailableNot Availableimplied
UDP-glucuronosyltransferase 2B7Not AvailableNot Availableimplied
UDP-glucuronosyltransferase 1-3Not AvailableNot Availableimplied
UDP-glucuronosyltransferase 1-8Not AvailableNot Availableimplied